GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LAVA Therapeutics NV (NAS:LVTX) » Definitions » Return-on-Tangible-Asset

LAVA Therapeutics NV (LAVA Therapeutics NV) Return-on-Tangible-Asset : -2.20% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is LAVA Therapeutics NV Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. LAVA Therapeutics NV's annualized Net Income for the quarter that ended in Mar. 2024 was $-2.21 Mil. LAVA Therapeutics NV's average total tangible assets for the quarter that ended in Mar. 2024 was $100.39 Mil. Therefore, LAVA Therapeutics NV's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -2.20%.

The historical rank and industry rank for LAVA Therapeutics NV's Return-on-Tangible-Asset or its related term are showing as below:

LVTX' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -110.12   Med: -53.03   Max: -22.58
Current: -25.09

During the past 5 years, LAVA Therapeutics NV's highest Return-on-Tangible-Asset was -22.58%. The lowest was -110.12%. And the median was -53.03%.

LVTX's Return-on-Tangible-Asset is ranked better than
62.45% of 1550 companies
in the Biotechnology industry
Industry Median: -40.335 vs LVTX: -25.09

LAVA Therapeutics NV Return-on-Tangible-Asset Historical Data

The historical data trend for LAVA Therapeutics NV's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LAVA Therapeutics NV Return-on-Tangible-Asset Chart

LAVA Therapeutics NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
-110.12 -108.78 -53.03 -22.58 -34.25

LAVA Therapeutics NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.01 -39.41 -30.27 -24.44 -2.20

Competitive Comparison of LAVA Therapeutics NV's Return-on-Tangible-Asset

For the Biotechnology subindustry, LAVA Therapeutics NV's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LAVA Therapeutics NV's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LAVA Therapeutics NV's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where LAVA Therapeutics NV's Return-on-Tangible-Asset falls into.



LAVA Therapeutics NV Return-on-Tangible-Asset Calculation

LAVA Therapeutics NV's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-41.974/( (143.425+101.71)/ 2 )
=-41.974/122.5675
=-34.25 %

LAVA Therapeutics NV's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-2.212/( (101.71+99.079)/ 2 )
=-2.212/100.3945
=-2.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


LAVA Therapeutics NV  (NAS:LVTX) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


LAVA Therapeutics NV Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of LAVA Therapeutics NV's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


LAVA Therapeutics NV (LAVA Therapeutics NV) Business Description

Traded in Other Exchanges
Address
Yalelaan 62, Utrecht, UT, NLD, 3584 CM
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.

LAVA Therapeutics NV (LAVA Therapeutics NV) Headlines

From GuruFocus

LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

By Stock market mentor Stock market mentor 02-06-2023

LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-03-2023

LAVA Therapeutics to Participate at the Jefferies Healthcare Conference

By GuruFocusNews GuruFocusNews 07-02-2022

LAVA Announces Annual Meeting of Shareholders

By GlobeNewswire GlobeNewswire 05-30-2023